Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
CC transcript
CATALYST BIOSCIENCES, INC. (CBIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/21/2023 8-K Quarterly results
12/27/2022 8-K Investor presentation
Docs: "by and among CATALYST BIOSCIENCES, INC., as the Buyer, and GNI GROUP LTD., and GNI HONG KONG LIMITED, as the Sellers Dated as of December 26, 2022",
"BUSINESS COMBINATION AGREEMENT",
"Certificate of Designation of Series X Convertible Preferred Stock",
"Amended and Restated Bylaws of Catalyst Biosciences, Inc",
"“Agreement”) is made and entered into as of [date] between Catalyst Biosciences, Inc., a Delaware corporation , and [name of director], a director, officer or member of the executive committee of the Company (“Indemnitee”",
"Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction",
"Presentation for investor conference call held by Catalyst Biosciences, Inc. on December 27, 2022"
01/12/2022 8-K Investor presentation
Docs: "Presentation slide deck"
09/28/2021 8-K Quarterly results
09/07/2021 8-K Quarterly results
08/05/2021 8-K Investor presentation, Quarterly results
Docs: "Catalyst Biosciences Reports Second Quarter 2021 Operating & Financial Results and Provides a Corporate Update",
"Presentation slide deck"
07/19/2021 8-K Investor presentation
Docs: "Complement Presentation slide deck",
"Corporate Presentation slide deck"
07/16/2021 8-K Investor presentation
Docs: "ARDS Complement Presentation slide deck",
"ARDS Complement Presentation slide deck"
05/06/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
01/26/2021 8-K Investor presentation
Docs: "Presentation slide deck"
12/14/2020 8-K Investor presentation
Docs: "Complement Presentation slide deck",
"Corporate Presentation slide deck"
11/17/2020 8-K Investor presentation
Docs: "Presentation slide deck"
09/17/2020 8-K Investor presentation
Docs: "Presentation slide deck"
06/18/2020 8-K Quarterly results
02/07/2020 8-K Investor presentation
Docs: "Presentation slide deck",
"Catalyst Biosciences Presents Positive Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa and Marzeptacog alfa Programs at the 13 th Annual EAHAD Congress"
06/21/2018 8-K Investor presentation
Docs: "Presentation at the JMP Securities 2018 Life Sciences Conference in New York, New York by Catalyst Biosciences, Inc. on June 21, 2018",
"Presentation at the JMP Securities 2018 Life Sciences Conference in New York, New York by Catalyst Biosciences, Inc. on June 21, 2018"
02/12/2018 8-K Investor presentation
Docs: "Presentation at the BIO CEO & Investor Conference in New York, NY by Catalyst Biosciences, Inc. on February 12, 2018",
"Presentation at the BIO CEO & Investor Conference in New York, NY by Catalyst Biosciences, Inc. on February 12, 2018"
12/11/2017 8-K Investor presentation
Docs: "Presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, GA, by Catalyst Biosciences, Inc. on December 9, 2017",
"Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference Subcutaneous delivery significantly increases half-life of CB 2679d to 98.7 hours"
09/14/2016 8-K Investor presentation
Docs: "Corporate Presentation presented September 13, 2016"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy